The DPP-4 inhibitor, sitagliptin, has been demonstrated to attenuate steatosis in a diet-induced NAFLD model [14] and ameliorate NAFLD activity score (NAS) by improving steatosis and ballooning in NAFLD patients [15]. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.